Key facts
- Atavistik Bio’s last known valuation is $435.0M (Feb 2026).
- It has raised $298.8M; the latest was Early Stage VC ($40.0M) in Feb 2026.
- Notable investors include RA Capital Management, Lux Capital, Nextech Invest, Regeneron Ventures, The Column Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Atavistik Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Atavistik Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atavistik Bio
Operator of a biopharmaceutical company intended to focus on the discovery and development of novel therapies for metabolic diseases and cancer. The company's platform maps metabolite protein interactions and analyzes cellular pathways through quantitative biochemical assays, computational modeling, and high-throughput screening workflows, enabling pharmaceutical and biotechnology organizations to identify novel drug targets, generate mechanistically informed therapeutic candidates, and evaluate biological relevance with greater precision.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 37
- Website
- atavistikbio.com/
- Ownership
- Privately Held (backing)
Atavistik Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atavistik Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atavistik Bio in its N-PORT filings yet. We sweep new filings monthly.